Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam and Isis secure rights to potential hepatitis treatments
The companies will now be able to use the research conducted at Stanford University to discover and develop new therapeutic products for the treatment of the disease. According
The companies will now be able to use the research conducted at Stanford University to discover and develop new therapeutic products for the treatment of the disease. According
The company is planning on testing two doses of its wound healing agent, Cardio Vascu-Grow, for topical application. The principal purpose of this first study is to test
The trial, which will enroll 45 patients at 14 medical centers across the US and Canada, will evaluate Xcytrin in combination with whole brain radiation therapy and stereotactic
The initial goal of this proof-of-concept phase Ib trial is to establish the maximum tolerated dose of PXD101 used in combination with carboplatin and/or paclitaxel, two drugs widely
Inovio is working closely on this project with Dr Connie Schmaljohn, chief of the department of molecular virology at the US Army Medical Research Institute of Infectious Diseases
The first indication that the company is seeking approval for is in the treatment of seizures associated with Lennox-Gastaut syndrome, a severe form of epilepsy that develops in
By the end of 2005, Nabi intends to announce preliminary safety and immunogenicity results from its European phase II study into NicVax, and be in a position to
Actiq is the first medication approved for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy
News of Merck’s intended equity buy runs concurrent to Geron’s plans to offer six million shares of its common stock in an underwritten offering made from effective shelf
ImClone Systems intends to use the UltiMAb system to develop human antibody product candidates against its disease targets, which are primarily in the area of oncology. Under the